{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:23:02Z","timestamp":1790310182897,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jtha.2023.08.032","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:17:08Z","timestamp":1693995428000},"page":"3450-3462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1"],"prefix":"10.1016","volume":"21","author":[{"given":"Brian","family":"O\u2019Mahony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Leavitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathelijne","family":"Peerlinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaan-Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Wee","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Giermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teh-Liane","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Cockrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pepperell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Chambost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda","family":"L\u00f3pez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Majerus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Yen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.08.032_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.24220","article-title":"Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia","volume":"90","author":"Witkop","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.08.032_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib4","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/PPA.S87659","article-title":"Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study","volume":"9","author":"Forsyth","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2023.08.032_bib5","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/ajh.24218","article-title":"Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status","volume":"90","author":"Curtis","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.08.032_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O\u2019Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jtha.2023.08.032_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.13754","article-title":"From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies","volume":"25","author":"Wiley","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.14171","article-title":"Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis","volume":"27","author":"O\u2019Hara","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/hae.14302","article-title":"Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A","volume":"27","author":"O\u2019Hara","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/hae.13111","article-title":"European retrospective study of real-life haemophilia treatment","volume":"23","author":"Berntorp","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hae.13731","article-title":"Health-related quality of life and health status in persons with haemophilia A with inhibitors: a prospective, multicentre, non-interventional study (NIS)","volume":"25","author":"Mahlangu","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib12","first-page":"1134","article-title":"Prevalence and interference of chronic pain among people with hemophilia: a systematic review and meta-analysis","volume":"22","author":"Paredes","year":"2021","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.jtha.2023.08.032_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2516.2010.02435.x","article-title":"The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study","volume":"17","author":"Klamroth","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib14","doi-asserted-by":"crossref","first-page":"7894","DOI":"10.4081\/hr.2019.7894","article-title":"Health status and quality of life in patients with severe hemophilia A: a cross-sectional survey","volume":"11","author":"Davari","year":"2019","journal-title":"Hematol Rep"},{"key":"10.1016\/j.jtha.2023.08.032_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ejh.13027","article-title":"Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study","volume":"100","author":"Buckner","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2023.08.032_bib16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2147\/PPA.S212723","article-title":"Interrelationship between depression, anxiety, pain, and treatment adherence in hemophilia: results from a US cross-sectional survey","volume":"13","author":"Witkop","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2023.08.032_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/hae.14571","article-title":"Pain, depression and anxiety in people with haemophilia from three Nordic countries: cross-sectional survey data from the MIND study","volume":"28","author":"Steen Carlsson","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/rth2.12195","article-title":"Hemophilia trials in the twenty-first century: defining patient important outcomes","volume":"3","author":"Konkle","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.032_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.17225\/jhp00176","article-title":"The potential impact of gene therapy on health-related quality of life (HRQoL) domains in haemophilia","volume":"8","author":"Bullinger","year":"2021","journal-title":"J\u00a0Haem Pract"},{"key":"10.1016\/j.jtha.2023.08.032_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12567","article-title":"Living with a \u201chemophilia-free mind\u201d - the new ambition of hemophilia care?","volume":"5","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.032_bib21","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5\u2013factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.08.032_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.08.032_bib23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.08.032_bib25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.08.032_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-140306","article-title":"Problem joints and their clinical and humanistic burden in children and adults with moderate and severe hemophilia A: CHESS Paediatrics and CHESS II [abstract]","volume":"136","author":"McLaughlin","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.08.032_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140950","article-title":"Examination and validation of a patient-centric joint metric: \u201cProblem Joint\u201d; empirical evidence from the CHESS US dataset [abstract]","volume":"136","author":"Burke","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.08.032_bib28","first-page":"354","article-title":"Examination and validation of a patient-centric joint metric: \u201cPROBLEM JOINT\u201d; empirical evidence from the CHESS Paediatrics dataset [abstract]","volume":"5","author":"Burke","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.032_bib29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1365-2516.2008.01812.x","article-title":"Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia","volume":"14","author":"Rentz","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/968081","article-title":"Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients","volume":"2014","author":"Varaklioti","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jtha.2023.08.032_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/PROM.S357555","article-title":"Psychometric validation of the Haemo-QOL-A in participants with hemophilia A treated with gene therapy","volume":"13","author":"Quinn","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.jtha.2023.08.032_bib32","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2023.08.032_bib33","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jtha.2023.08.032_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1081\/COPD-200052090","article-title":"The minimally clinically important difference in generic utility-based measures","volume":"2","author":"Kaplan","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.jtha.2023.08.032_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2516.2006.01186.x","article-title":"Measuring patients\u2019 perceptions on their functional abilities: validation of the Haemophilia Activities List","volume":"12","author":"van Genderen","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jval.2014.07.003","article-title":"Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE)","volume":"17","author":"Recht","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2023.08.032_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jtha.2023.08.032_bib38","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/hae.12759","article-title":"Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials","volume":"21","author":"Oladapo","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/hae.13313","article-title":"Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies","volume":"23","author":"Pierce","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.14278","article-title":"Evidence of a disability paradox in patient-reported outcomes in haemophilia","volume":"27","author":"O\u2019Hara","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib41","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/hae.14270","article-title":"Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study","volume":"27","author":"Oldenburg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib42","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.032_bib43","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s12325-020-01374-2","article-title":"Comparing physician and patient perspectives on prophylactic treatment with BAY 94-9027 for severe haemophilia a: a post hoc analysis","volume":"37","author":"Lalezari","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtha.2023.08.032_bib44","first-page":"386","article-title":"Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B","volume":"25","author":"Burke","year":"2022","journal-title":"J\u00a0Med Econ"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623006633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623006633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:39:40Z","timestamp":1761536380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623006633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1538783623006633"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.08.032","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}